- Home
- MED vs KLRS Comparison
MED vs KLRS Comparison
Compare MED & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MED | KLRS |
|---|---|---|
| Founded | 1980 | 2019 |
| Country | United States | United States |
| Employees | N/A | 20 |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.0M | 117.1M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | MED | KLRS |
|---|---|---|
| Price | $12.16 | $4.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $12.00 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 154.1K | 83.7K |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $934,842,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.22 | $2.14 |
| 52 Week High | $15.37 | $11.88 |
Technical Indicators
Market Signals| Indicator | MED | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 49.38 | 29.80 |
| Support Level | $10.10 | $3.49 |
| Resistance Level | $12.21 | $5.43 |
| Average True Range (ATR) | 0.46 | 0.36 |
| MACD | -0.14 | -0.04 |
| Stochastic Oscillator | 18.12 | 3.37 |
Price Performance
Historical ComparisonAbout MED MEDIFAST INC
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. The company provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. The company is focused on offering talent to Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.